Contineum Therapeutics, Inc.
CTNM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001855175
In the last 90 days, Contineum Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 102 institutions reported holding it in 13F filings for Q2 2026, worth $500.6M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q3 2025 vs. Q2 2025
How the institutions holding Contineum Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 70 | 1 | 62 | −7 |
| Shares | 13.9M | 169.7K | 17.5M | +3.79M (+27.6%) |
| Value | $55.4M | $673.8K | $205.7M | +$151.0M (+275.9%) |
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Contineum Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ra Capital Management, L.P. | 2,122,000 | $24.9M | 0.31% |
| Balyasny Asset Management LLC | 951,320 | $11.2M | 0.02% |
| Silverarc Capital Management, LLC | 166,161 | $1.95M | 0.28% |
| Eversept Partners, LP | 134,619 | $1.58M | 0.12% |
| Trexquant Investment LP | 29,310 | $344.4K | 0.00% |
| Baker Ellis Asset Management LLC | 19,500 | $229.1K | 0.03% |
| Bailard, Inc. | 12,350 | $145.1K | 0.00% |
| Mariner, LLC | 10,420 | $122.4K | 0.00% |
| Simplex Trading, LLC | 895 | $10.0K | 0.00% |
| Group One Trading, L.P. | 500 | $5.88K | 0.00% |
| Fortitude Family Office, LLC | 445 | $5.23K | 0.00% |
| Point72 Europe (London) LLP | 179 | $2.10K | 0.00% |
| Optiver Holding B.V. | 104 | $1.22K | 0.00% |
| SRS Capital Advisors, Inc. | 8 | $94 | 0.00% |
Sold out (21)
Institutions that held Contineum Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Saturn V Capital Management LLC | 319,348 | $1.27M |
| Monaco Asset Management SAM | 75,000 | $297.8K |
| Two Sigma Advisers, LP | 43,200 | $171.5K |
| Y-Intercept (Hong Kong) Ltd | 35,156 | $139.6K |
| AQR Capital Management LLC | 25,156 | $99.9K |
| Jane Street Group, LLC | 20,321 | $80.7K |
| Jain Global LLC | 19,590 | $77.8K |
| Jacobs Levy Equity Management, Inc | 17,245 | $68.5K |
| Citadel Advisors LLC | 16,489 | $65.5K |
| Prelude Capital Management, LLC | 13,920 | $55.3K |
| Marex Group plc | 11,400 | $45.3K |
| Qube Research & Technologies Ltd | 10,924 | $43.4K |
| Citigroup Inc | 1,774 | $7.04K |
| JPMorgan Chase & Co | 1,108 | $4.40K |
| Harbor Capital Advisors, Inc. | 145 | $1.00K |
| Point72 (DIFC) Ltd | 65 | $258 |
| GAMMA Investing LLC | 60 | $238 |
| Nisa Investment Advisors, LLC | 46 | $183 |
| Clearstead Advisors, LLC | 33 | $132 |
| Cubist Systematic Strategies, LLC | 24 | $95 |
| Advisor Group Holdings, Inc. | 10 | $70 |
Not filed for Q3 2025 yet (1)
Institutions that held Contineum Therapeutics, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Norges Bank | 169,729 | $673.8K |